|
MechanismTubulin inhibitors |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseSuspended |
First Approval Ctry. / Loc.- |
First Approval Date- |
EndoTAG-1联合吉西他滨与吉西他滨单药治疗可测量局部晚期和/或转移性胰腺癌有效性和安全性的多中心、随机、对照、开放、Ⅲ期临床研究
[Translation] A multicenter, randomized, controlled, open-label, phase III clinical study to measure the efficacy and safety of EndoTAG-1 combined with gemcitabine versus gemcitabine alone in the treatment of locally advanced and/or metastatic pancreatic cancer
本研究的目的是评价EndoTAG-1联合吉西他滨治疗较之吉西他滨单药治疗局部晚期和/或转移性胰腺癌患者的有效性和安全性
[Translation] The purpose of this study is to evaluate the efficacy and safety of EndoTAG-1 combined with gemcitabine compared with gemcitabine alone in patients with locally advanced and/or metastatic pancreatic cancer.
100 Clinical Results associated with Beijing Gorjest Technology Co., Ltd.
0 Patents (Medical) associated with Beijing Gorjest Technology Co., Ltd.
100 Deals associated with Beijing Gorjest Technology Co., Ltd.
100 Translational Medicine associated with Beijing Gorjest Technology Co., Ltd.